Friday, December 23, 2016 Written by David Persing M.D., Ph.D., Chief Medical and Technology Officer, Cepheid

From the Editor

I am privileged at Cepheid to work with the some of the best minds in the diagnostics business. In this month's issue of the On-Demand newsletter, Dr. Ellen Jo Baron highlights the role of decentralized molecular testing in TB diagnostics, with a special focus on the nearly impossible challenge of diagnosing pediatric TB. This is a truly moving story which begs the question: Is there not a better solution? Cepheid is committed to developing less invasive diagnostic tools for TB in kids and in all patients with HIV where current diagnostic options are, simply put, woefully suboptimal. I am optimistic that Ellen Jo and her colleagues inside and outside the company will come up with a better way.

Also highlighted in this issue is 1) the need for suitable external controls for molecular diagnostic assays, and 2) the impact of the emergence of the 027 strain of C. difficile. We hope you enjoy reading this information as we much as we have in preparing it.